GC376

VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant

Retrieved on: 
Tuesday, July 27, 2021
Coronaviridae, Sarbecovirus, Zoonoses, Biocides, Severe acute respiratory syndrome coronavirus 2, Variants of SARS-CoV-2, Antiviral drug, Virucide, COVID-19, Coronavirus, Severe acute respiratory syndrome, GC376

New antiviral testing demonstrates SPL7013, the antiviral agent in VIRALEZE nasal spray, has potent virucidal activity against the globally significant Delta variant of SARS-CoV-2, reducing infectivity of the virus by >99.99% after 30 seconds of exposure

Key Points: 
  • New antiviral testing demonstrates SPL7013, the antiviral agent in VIRALEZE nasal spray, has potent virucidal activity against the globally significant Delta variant of SARS-CoV-2, reducing infectivity of the virus by >99.99% after 30 seconds of exposure
    SPL7013, the antiviral agent in VIRALEZE, has now been shown in laboratory studies to be virucidal against all four coronavirus SARS-CoV-2 Variants of Concern: Alpha, Beta, Gamma and Delta
    These latest data further illustrate the broad-spectrum antiviral activity of SPL7013, which has been demonstrated against multiple respiratory viruses, including influenza and RSV, as well as its consistent and potent activity against multiple SARS-CoV-2 variants
    VIRALEZE antiviral nasal spray is registered for sale in Europe and India, and available in certain markets online.
  • MELBOURNE, Australia, July 27, 2021 /PRNewswire/-- Starpharma today announced new data demonstrating that SPL7013, the antiviral agent in VIRALEZE nasal spray, is active against the highly transmissible Delta variant of SARS-CoV-2, achieving more than 99.99% reduction of infectious virus in laboratory-based virucidal assays.
  • The antiviral testing of SPL7013 was conducted in the laboratory of virologist, Professor Philippe Gallay, atThe Scripps Research Institute in the US, where previous studies have also demonstrated potent antiviral and virucidal activity of SPL7013 against multiple variants of SARS-CoV-2, including the globally important Alpha, Beta and Gamma 'Variants of Concern'.
  • Percent reductions of infectious virus achieved with 10 mg/mL SPL7013 (the concentration in VIRALEZE) are shown in the table below.

Anivive's GC376 Reduces COVID-19 Replication, Shows Potential as New Post-Infection Treatment

Retrieved on: 
Friday, July 23, 2021
Antiviral drugs, Medical specialties, Health, Zoonoses, GC376, COVID-19, Virus, Protease inhibitor, Vaccine, Rupintrivir, 3CLpro-1

While vaccines to help prevent COVID-19 are now expansively available in the United States, the need for post-infection treatment options is on the rise.

Key Points: 
  • While vaccines to help prevent COVID-19 are now expansively available in the United States, the need for post-infection treatment options is on the rise.
  • GC376 is a protease inhibitor, designed to block the replication process and stop the virus from spreading.
  • GC376 has the potential to be a One Health medicine, providing therapeutic benefits to both pets and people.
  • Anivive has filed a pre-Investigational New Drug request with the Food and Drug Administration to evaluate GC376 as a post-infection treatment of COVID-19 in humans.

Verge Genomics Presents Preclinical Data Supporting Broad-Spectrum Potential of Its Novel, Oral Antiviral at the 31st European Congress of Clinical Microbiology & Infectious Diseases

Retrieved on: 
Wednesday, July 7, 2021
Health, Infectious diseases, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Coronaviridae, Sarbecovirus, Antiviral drug, Severe acute respiratory syndrome, COVID-19 drug repurposing research, GC376, the Preclinical Study, PIKfyve, Verge Genomics, THE PRECLINICAL STUDY, PIKFYVE, VERGE GENOMICS

The results will be presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) online meeting being held July 9-12, 2021.

Key Points: 
  • The results will be presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) online meeting being held July 9-12, 2021.
  • There remains an urgent need for oral antiviral treatments for SARS-CoV-2 and its variants, said Alice Zhang, CEO and Co-Founder of Verge Genomics.
  • Verge has demonstrated potent antiviral activity in vitro and improvement of SARS-CoV-2-induced pathology in vivo by the PIKfyve inhibitor, VRG101.
  • Verge is focused on developing therapeutics for serious genetic diseases using human genomics and machine learning.

Sunshine Biopharma Upgrades COVID-19 Provisional Patent Application to Full PCT Application

Retrieved on: 
Tuesday, May 4, 2021
3C-like protease, Sarbecovirus, Peptidase, Virology, NSP5, Protease, Branches of biology, POL, Cysteine protease, Proteins, Severe acute respiratory syndrome–related coronavirus, GC376

Sunshine had originally filed a provisional patent application covering the COVID-19 treatment on May 22, 2020.

Key Points: 
  • Sunshine had originally filed a provisional patent application covering the COVID-19 treatment on May 22, 2020.
  • SARS-CoV-2 produces several functional proteins in infected human cells by cleaving them from two overlapping viral polyproteins, pp1a and pp1ab.
  • One of these functional proteins is a cysteine protease referred to as the main protease, Mpro (also called 3CLpro and nsp5).
  • Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4.

Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic Infections

Retrieved on: 
Monday, March 8, 2021
Protease inhibitor, HIV/AIDS, Antiviral drugs, Discovery and development of HIV-protease inhibitors, GC376

Ph.D., Executive Vice President, Head of Small Molecule Medicinal Chemistry and European Site Head at Aligos.

Key Points: 
  • Ph.D., Executive Vice President, Head of Small Molecule Medicinal Chemistry and European Site Head at Aligos.
  • We have also observed highly specific, selective activity in vitro that is consistent with the robust viral inhibition we see in aggressive animal models of infection.
  • These findings represent a significant advance toward a highly targeted therapeutic candidate that is urgently needed as the COVID-19 pandemic persists.
  • The demonstration of potent preclinical activity in Aligos viral protease inhibitor candidate is an important advancement toward this goal.

Atea Pharmaceuticals Announces Publication of Preclinical Data Highlighting Potent Activity of AT-527 Against SARS-CoV-2

Retrieved on: 
Monday, February 8, 2021
Sarbecovirus, Antiviral drugs, Medical specialties, Medicine, Respiratory diseases, Animal virology, Coronavirus, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Coronavir, GC376

BOSTON, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company, today announced the publication of new data highlighting the highly potent in vitro antiviral activity of AT-527 against SARS-CoV-2.

Key Points: 
  • BOSTON, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company, today announced the publication of new data highlighting the highly potent in vitro antiviral activity of AT-527 against SARS-CoV-2.
  • These new data underscore AT-527s potential to treat COVID-19 and to have an impact on global health, said Jean-Pierre Sommadossi, Ph.D., Founder and Chief Executive Officer of Atea Pharmaceuticals.
  • The results demonstrated in several in vitro assays that AT-527 has highly potent antiviral activity against several human coronaviruses, including SARS-CoV-2, the causative agent of COVID-19.
  • AT-527 was activated in cultured normal human nasal and bronchial epithelial cells, which are the primary targets of SARS-CoV-2 infection.

Aligos Therapeutics Presents Update on Development of SARS-CoV-2 Therapeutic Candidate and Screening Method in Collaboration with KU Leuven at RespiDART & Emerging Viruses 2020

Retrieved on: 
Thursday, December 17, 2020
Sarbecovirus, Zoonoses, Respiratory diseases, Medical specialties, 3C-like protease, Severe acute respiratory syndrome coronavirus, Coronavirus, Severe acute respiratory syndrome, Severe acute respiratory syndrome–related coronavirus, GC376

The presentation highlighted the companys progress with developing a SARS-CoV-2 therapeutic candidate, as well as the development of a screening method to assess potential candidates.

Key Points: 
  • The presentation highlighted the companys progress with developing a SARS-CoV-2 therapeutic candidate, as well as the development of a screening method to assess potential candidates.
  • Aligos performed all research in collaboration with Belgian University KU Leuven, in particular its Centre for Drug Design and Discovery (CD3), and the Rega Institute for Medical Research.
  • Coronaviral 3CLpro is a promising therapeutic target, as it is essential and conserved among coronaviruses but is not found in humans.
  • Cathepsin L has been shown to be involved in a highly redundant entry pathway of SARS-CoV-2 into different cell types.

COVISTAT, a Subsidiary of Ensysce Biosciences Inc, a California Based Company With a Mission to Solve the Opioid Crisis, Is Commencing Phase 1 Study of Novel COVID-19 Treatment

Retrieved on: 
Monday, September 28, 2020
Science, Biotechnology, Research, Pharmaceutical, Managed care, Health, Infectious diseases, Clinical trials, Sarbecovirus, Antivirals, Respiratory diseases, Medical specialties, Infectious diseases, Zoonoses, Animal virology, Coronavirus, Coronavir, Severe acute respiratory syndrome, GC376, Coronavirus disease

Nafamostat, an ultra-potent protease inhibitor and an ingredient from Ensysces opioid overdose protection platform, is being developed as an oral treatment for COVID-19.

Key Points: 
  • Nafamostat, an ultra-potent protease inhibitor and an ingredient from Ensysces opioid overdose protection platform, is being developed as an oral treatment for COVID-19.
  • Nafamostat has a novel mechanism of action for treating COVID-19 as a potent protease inhibitor that blocks SARS-CoV-2 viral entry into host cells.
  • Because of this it has antiviral properties against other coronaviruses including the Middle East Respiratory Syndrome (MERS), SARS and now SARS-CoV-2.
  • Ensysce Biosciences is developing two new classes of opioid pain products (Trypsin Activated Abuse Protected TAAP) with overdose protection (MPAR).

AB Science: New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19

Retrieved on: 
Wednesday, September 2, 2020
Sarbecovirus, Antivirals, Antiviral drug, Biocides, Medical specialties, Infectious diseases, 3C-like protease, Severe acute respiratory syndrome, Animal diseases, GC376

This research has shown for the first time that masitinib exerts a direct anti-viral effect on the SARS-CoV-2 virus, under in vitro conditions.

Key Points: 
  • This research has shown for the first time that masitinib exerts a direct anti-viral effect on the SARS-CoV-2 virus, under in vitro conditions.
  • These data identify a novel mechanism of action by which masitinib could exert an anti-viral effect against viral diseases by targeting virus protease.
  • In particular, results provide a new compelling biological rationale for the use of masitinib in the treatment of COVID-19.
  • X-ray crystallography revealed that masitinib directly binds to the active site of 3CLpro, thereby having a direct antiviral activity by blocking its enzymatic activity.

Anivive Repurposes Veterinary Drug GC376 for COVID-19 And Submits Pre-IND to FDA

Retrieved on: 
Tuesday, May 26, 2020
Veterinary, Biotechnology, Pharmaceutical, Health, FDA, Infectious diseases, Clinical trials, Other Health, Zoonoses, SARS coronavirus main proteinase, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Tree of life biology), Veterinary medicine, Medicine, Epidemiology, GC376, Anivive Lifesciences

We look forward to our discussions with the FDA and advancing toward a clinical trial, says Anivive CEO and Founder Dylan Balsz.

Key Points: 
  • We look forward to our discussions with the FDA and advancing toward a clinical trial, says Anivive CEO and Founder Dylan Balsz.
  • Internal and third-party research suggests that GC376 is also highly active against the protease in SARS-CoV-2, 3CLpro, that causes COVID-19.
  • Anivive remains dedicated to developing GC376 for veterinary patients but, given the current pandemic and scarcity of effective therapies, is also exploring the use of GC376 in humans to help combat COVID-19.
  • Anivive has repurposed GC376 to help combat COVID-19 while maintaining their commitment to bring the product to the veterinary market.